GNPX Genprex, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595248 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-233.7%
ROA-160.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets21.7%
Debt / equity0.00x
Current ratio4.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $0 | $0 | $0 |
| R&D expense | $9.43M | $10.54M | $17.62M | $11.51M | $8.97M |
| SG&A expense | $6.09M | $10.63M | $13.43M | $12.30M | $11.68M |
| Operating income | -$15.52M | -$21.17M | -$31.06M | -$23.83M | -$20.67M |
| Income tax | $0 | $2,650 | $0 | $0 | — |
| Net income | -$16.23M | -$21.11M | -$30.86M | -$23.74M | -$20.66M |
| EBITDA | -$15.52M | -$21.17M | -$31.04M | -$23.81M | -$20.65M |
| EPS (basic) | -17.40 | -266.89 | -22.56 | -19.80 | -0.44 |
| EPS (diluted) | — | — | — | — | -0.42 |
| Weighted avg. shares (diluted) | — | — | — | — | 47.10M |
| Balance sheet | |||||
| Cash & equivalents | $7.83M | $1.60M | $6.74M | $20.95M | $38.63M |
| Receivables | — | — | $0 | $34,852 | $0 |
| Current assets | $8.36M | $2.08M | $7.53M | $21.47M | $39.14M |
| PP&E, net | $0 | $0 | $7,859 | $23,032 | $48,608 |
| Intangibles | — | $0 | $773,478 | $702,095 | $642,360 |
| Total assets | $10.16M | $4.12M | $10.67M | $25.09M | $42.86M |
| Current liabilities | $2.17M | $2.50M | $3.25M | $2.81M | $1.59M |
| Total liabilities | $2.20M | $2.50M | $3.25M | $2.81M | $1.59M |
| Shareholders' equity | $7.96M | $1.62M | $7.42M | $22.27M | $41.28M |
| Shares outstanding | 149,811 | 217,234 | 1.49M | 1.20M | 47.87M |
| Cash flow statement | |||||
| Operating cash flow | -$15.31M | -$17.92M | -$24.74M | -$17.62M | -$14.28M |
| Capital expenditure | — | — | — | $0 | $31,700 |
| Free cash flow | — | — | — | -$17.62M | -$14.32M |
| Investing cash flow | $0 | $774,644 | -$71,214 | -$59,735 | -$83,796 |
| Financing cash flow | $21.54M | $12.01M | $10.59M | $6,426 | $25.68M |
| Depreciation & amortization | $0 | $6,693 | $15,004 | $25,575 | $22,534 |
| Stock-based compensation | $300,000 | $3.30M | $5.41M | $4.73M | $5.35M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.